<DOC>
	<DOCNO>NCT02939235</DOCNO>
	<brief_summary>The purpose study evaluate difference pharmacokinetics pharmacodynamics ticagrelor active metabolite patient receive ticagrelor morphine follow metoclopramide versus patient treat ticagrelor morphine alone unstable angina pectoris .</brief_summary>
	<brief_title>Influence Metoclopramide Ticagrelor Pharmacokinetics Pharmacodynamics Patients With Unstable Angina Pectoris Concomitant Treatment With Morphine</brief_title>
	<detailed_description>According contemporary guideline , ticagrelor recommend antiplatelet agent acute coronary syndrome , include unstable angina pectoris . Quick platelet inhibition play pivotal role treatment acute coronary syndrome . As evidenced IMPRESSION study , analgesia morphine delay platelet inhibition patient acute myocardial infarction . On hand , result MOJITO study prove administration crush ticagrelor tablet lead quick platelet blockage . Taking consideration , create pharmacokinetic/pharmacodynamic study aim evaluate difference patient receive crushed ticagrelor orally follow either 1 ) combination intravenous morphine metoclopramide 2 ) intravenous morphine alone . The primary study outcome time need ticagrelor active metabolite reach maximum plasma concentration study arm . Secondary outcome include ticagrelor AR-C124900XX maximum concentration area plasma concentration curve agent . Platelet reactivity assess Multiplate Analyzer study participant nine predefined time point .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Diagnosis unstable angina Male nonpregnant female , age 1880 year Provision inform consent angiography PCI GRACE score &lt; 140 pt treatment ticlopidine , clopidogrel , prasugrel ticagrelor within 14 day study enrollment current treatment morphine opioid `` mi '' receptor agonist hypersensitivity ticagrelor current treatment oral anticoagulant chronic therapy lowmolecularweight heparin active bleed history intracranial hemorrhage recent gastrointestinal bleeding ( within 30 day ) history coagulation disorder platelet count less &lt; 100 x10^3/mcl hemoglobin concentration le 10.0 g/dl history moderate severe hepatic impairment history major surgery severe trauma ( within 3 month ) risk bradycardic event judge investigator second third degree atrioventricular block screen eligibility history asthma severe chronic obstructive pulmonary disease kidney disease require dialysis manifest infection inflammatory state Killip class III IV screen eligibility respiratory failure history severe chronic heart failure ( NYHA class III IV ) concomitant therapy strong CYP3A inhibitor ( ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazadone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir ) strong CYP3A inducer ( rifampicin , phenytoin , carbamazepine , dexamethasone , phenobarbital ) within 14 day study treatment body weight 50 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>